Duzallo

Active Ingredient(s): Lesinurad + Allopurinol
FDA Approved: * August 18, 2017
Pharm Company: * ARDEA BIOSCIENCES INC
Category: Gout

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Duzallo Overview

Lesinurad/allopurinol (trade name Duzallo) is a fixed-dose combination drug for the treatment of gout. It contains 200 mg of lesinurad and 300 mg of allopurinol. In August 2017, the US Food and Drug Administration approved it for the treatment of hyperuricemia associated with gout in patients for whom target serum uric acid levels have not been achieved with allopurinol alone.[1] References ^ "FDA Clears First Fixed-Dose Combination Treatment for Gout". Medscape. August 21, 2017. T...

Read more Duzallo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lesinurad/allopurinol

Recent Duzallo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lesinurad + Allopurinol
  • Tablet, Chewable, Tablet, Capsule: 200 + 200, 200 + 300
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (6 results)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 21 September 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.